Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics

This publication has 35 references indexed in Scilit:

• Efficacy and safety of rosuvastatin in treatment of dyslipidemia
  American Journal of Health-System Pharmacy, 2005
• The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
  Clinical Pharmacology & Therapeutics, 2004
• Organic anion‐transporting polypeptide (OATP) transporter family and drug disposition
  European Journal of Clinical Investigation, 2003
• Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers
  Clinical Therapeutics, 2003
• Comparative pharmacology of rosuvastatin
  Atherosclerosis Supplements, 2003
• Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.
  The American Journal of Cardiology, 2001
• The evolving role of statins in the management of atherosclerosis
  Journal of the American College of Cardiology, 1999
• A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
  Journal of Biological Chemistry, 1999
• The response‐to‐retention hypothesis of atherogenesis reinforced
  Current Opinion in Lipidology, 1998
• Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible Mechanisms
  New England Journal of Medicine, 1995